- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Pharmala Biotech Holdings Inc: Pharmala Biotech talks 2024 revenue, closes financing | 1 | Stockwatch | ||
| Fr | PharmAla Biotech: PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement | 2 | GlobeNewswire (USA) | ||
| 13.12. | PharmAla Biotech: PharmAla Announces Private Placement | 3 | GlobeNewswire (USA) | ||
| 14.11. | PharmAla Biotech: PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License | 2 | GlobeNewswire (USA) | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 07.11. | PharmAla Biotech: PharmAla to supply LaNeo MDMA for Clinical Trial at Yale | 2 | GlobeNewswire (USA) | ||
| 21.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Mt. Sinai hospital | 4 | Stockwatch | ||
| 21.10. | PharmAla Biotech: PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 08.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to University of Texas | 2 | Stockwatch | ||
| 08.10. | PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial | 4 | Benzinga.com | ||
| 08.10. | PharmAla Biotech: PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 02.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Harvard's Maclean | 1 | Stockwatch | ||
| 02.10. | PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial | 2 | Benzinga.com | ||
| 02.10. | PharmAla to supply Harvard Medical School trial with MDMA | 4 | The Market Herald Canada | ||
| 02.10. | PharmAla Biotech: PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 11.09. | Pharmala Biotech Holdings Inc: Pharmala to supply MDMA for Johns Hopkins trial | 1 | Stockwatch | ||
| 11.09. | PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract | 2 | Benzinga.com | ||
| 11.09. | PharmAla Biotech: PharmAla to supply Johns Hopkins Medicine for Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 22.08. | Pharmala Biotech Holdings Inc: Pharmala appoints Avery as CFO | 1 | Stockwatch | ||
| 22.08. | PharmAla Biotech appoints William Avery as finance chief | 1 | Seeking Alpha | ||
| 22.08. | PharmAla Biotech: PharmAla Launches MDMA Clinical Trial Tool for Researchers | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Qiagen NV-Aktie läuft heute schlechter (42,62 €) | Im Minus liegt aktuell der Anteilsschein von Qiagen NV . Die Aktie kostete zuletzt 42,62 Euro. Am Aktienmarkt hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,62 Prozent verbilligt.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec-Aktie: Geht es jetzt weiter bergab - oder kommt doch noch in Kürze der große Durchbruch? Wir analysieren und verraten Ihnen unsere Tradingidee! | © Foto: SymbolbildWas passiert mit Evotec? Die Aktie des Hamburger Biotech-Unternehmens hatte 2024 kein einfaches Jahr: Fast 60 Prozent Kursverlust, Gerüchte über eine Übernahme und die Rückkehr in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.
